Conexeu Sciences (NASDAQ:CNXU) Releases Quarterly Earnings Results, Misses Expectations By $0.19 EPS

Conexeu Sciences (NASDAQ:CNXU) issued its quarterly earnings data on Monday. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.19), Zacks reports.

Conexeu Sciences Price Performance

Conexeu Sciences stock traded up $0.54 during midday trading on Monday, reaching $5.00. The stock had a trading volume of 189,629 shares, compared to its average volume of 157,771. The business has a fifty day moving average price of $8.09. Conexeu Sciences has a 12 month low of $4.19 and a 12 month high of $18.79. The company has a market cap of $133.80 million and a P/E ratio of -45.45.

Insider Buying and Selling

In other news, Director Lynn Sebastian Purcell acquired 202,500 shares of the firm’s stock in a transaction dated Thursday, June 18th. The stock was purchased at an average price of $0.80 per share, for a total transaction of $162,000.00. Following the completion of the acquisition, the director directly owned 2,734,240 shares in the company, valued at $2,187,392. The trade was a 8.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on CNXU shares. HC Wainwright began coverage on Conexeu Sciences in a research note on Monday, June 22nd. They issued a “buy” rating and a $20.00 price objective on the stock. Wall Street Zen raised shares of Conexeu Sciences to a “hold” rating in a research note on Saturday, May 30th. Weiss Ratings assumed coverage on shares of Conexeu Sciences in a research report on Monday, August 17th. They set a “sell (e-)” rating for the company. Finally, Zacks Research upgraded shares of Conexeu Sciences to a “hold” rating in a report on Monday, June 29th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $20.00.

Conexeu Sciences Company Profile

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.